Nicole Schroeder, Danielle R. Castiello, Laura A. Siemianowski
{"title":"吸入依前列醇治疗急性呼吸窘迫综合征","authors":"Nicole Schroeder, Danielle R. Castiello, Laura A. Siemianowski","doi":"10.1097/01.CCN.0000534919.47806.75","DOIUrl":null,"url":null,"abstract":"Abstract: Acute respiratory distress syndrome (ARDS) is associated with high rates of mortality. Inhaled nitric oxide and inhaled epoprostenol (iEPO) are inhaled pulmonary vasodilators used for adjunctive management in patients with severe ARDS. This article describes the safe and effective use of iEPO in patients with refractory hypoxemia.","PeriodicalId":19344,"journal":{"name":"Nursing Critical Care","volume":" ","pages":"6–13"},"PeriodicalIF":0.0000,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.CCN.0000534919.47806.75","citationCount":"1","resultStr":"{\"title\":\"Inhaled epoprostenol for acute respiratory distress syndrome\",\"authors\":\"Nicole Schroeder, Danielle R. Castiello, Laura A. Siemianowski\",\"doi\":\"10.1097/01.CCN.0000534919.47806.75\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract: Acute respiratory distress syndrome (ARDS) is associated with high rates of mortality. Inhaled nitric oxide and inhaled epoprostenol (iEPO) are inhaled pulmonary vasodilators used for adjunctive management in patients with severe ARDS. This article describes the safe and effective use of iEPO in patients with refractory hypoxemia.\",\"PeriodicalId\":19344,\"journal\":{\"name\":\"Nursing Critical Care\",\"volume\":\" \",\"pages\":\"6–13\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1097/01.CCN.0000534919.47806.75\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nursing Critical Care\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/01.CCN.0000534919.47806.75\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Nursing\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nursing Critical Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.CCN.0000534919.47806.75","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Nursing","Score":null,"Total":0}
Inhaled epoprostenol for acute respiratory distress syndrome
Abstract: Acute respiratory distress syndrome (ARDS) is associated with high rates of mortality. Inhaled nitric oxide and inhaled epoprostenol (iEPO) are inhaled pulmonary vasodilators used for adjunctive management in patients with severe ARDS. This article describes the safe and effective use of iEPO in patients with refractory hypoxemia.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
